Therefore, MED12 mutation-driven leiomyoma disease pathogenesis is more likely a result of CDK8 kinase activity defects, and not cyclin C-CDK8 binding defects, and future work will be required to identify the kinase substrate of the CDK8 submodule. This evidence concerns the gene MED12 and leiomyoma.